-
Mouse Multiplex ELISA Panels(Page)
Mouse Multiplex ELISA & Cytokine Assay Panels | Assay Genie
Multiplex Assays(Page)GeniePlex Multiplex Assays | Bead-Based Multiplex Immunoassays | Assay Genie
Macrophage Activation: A Keystone in Immune Response and Therapeutic Potential(Post)In the intricate tapestry of the immune system, macrophages play a pivotal role, orchestrating a wide range of biological responses that protect the body against pathogens, remove cellular debris,
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
chemokine receptors and ligands(Post)Chemokines are highly conserved cytokines that control the movement of cells around the body. All 45 members of the chemokine family can be divided into 4 subfamilies depending on th
Acute Lymphoblastic Leukaemia Review | Assay Genie(Post)Incidence rate of Acute Lymphoblastic Leukaemia Acute lymphoblastic leukaemia (ALL) is one of the most common malignant diseases diagnosed in children. It
Renal and Hepatic Function Assays(Post)Hepatic Function Assays Liver function assays are a suite of tests designed to assess the health and efficacy of our vital
Co-Inhibitory Checkpoints Beyond PD-1: CTLA-4, LAG-3 and TIM-3(Post)PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are
Non-Alcoholic Fatty Liver Disease (NAFLD) - Biomarkers(Post)Key Points Non-alcoholic fatty liver disease (NAFLD) refe
NLRP3 Inflammasome & Cytokine Secretion(Post)Nod-like receptors Nod like receptors (NLRs) are a versatile family of relatively recently discovered intracellular receptors which have a br
How we can target the underlying immune processes in pathological inflammation in obesity, cancer and liver disease.(Post)Dr. Melissa Conroy, TTMI I am an immunologist and senior research fellow in the Cancer Immunology and Immunotherapy Group, Department of Surgery at Trinity
Phosphorothioate: Enhancing Stability in Oligonucleotide-Based Therapies(Post)Phosphorothioate is a chemical modification commonly used in oligonucleotide-based therapies to enhance the stability and efficacy of therapeutic nucleic acids. In this modification, one
Enhancing PD-L1 Stability Through EZH2 Inhibition(Post)Enhancing PD-L1 Stability: The Role of EZH2 InhibitionIn recent years, the role of PD-L1 (Programmed Death-Ligand 1) in cancer immunotherapy has garnered significant attention, particularly regarding
PVR: Balancing Immune Activation and Suppression in Cancer(Post)PVR (Poliovirus receptor), also known as CD155, is a molecule that plays a dual role in regulating the immune response within the tumor microenvironment. While initially discovered as a r
CD27 Activation: Strengthening the Immune Army Against Cancer(Post)Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activa
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Fezakinumab: Exploring Its Mechanism and Clinical Potential(Post)Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
Icrucumab: Exploring the Role of Anti-Angiogenic Therapy in Cancer Research(Post)Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe